214 related articles for article (PubMed ID: 12588973)
1. Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.
Rayet B; Fan Y; Gélinas C
Mol Cell Biol; 2003 Mar; 23(5):1520-33. PubMed ID: 12588973
[TBL] [Abstract][Full Text] [Related]
2. Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.
Chen C; Agnès F; Gélinas C
Mol Cell Biol; 1999 Jan; 19(1):307-16. PubMed ID: 9858554
[TBL] [Abstract][Full Text] [Related]
3. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
4. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
Epinat JC; Dvorin EL; Gilmore TD
Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
[TBL] [Abstract][Full Text] [Related]
5. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
6. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Kirchner D; Duyster J; Ottmann O; Schmid RM; Bergmann L; Munzert G
Exp Hematol; 2003 Jun; 31(6):504-11. PubMed ID: 12829026
[TBL] [Abstract][Full Text] [Related]
8. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.
Romieu-Mourez R; Kim DW; Shin SM; Demicco EG; Landesman-Bollag E; Seldin DC; Cardiff RD; Sonenshein GE
Mol Cell Biol; 2003 Aug; 23(16):5738-54. PubMed ID: 12897145
[TBL] [Abstract][Full Text] [Related]
9. Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappaB family.
Fan G; Fan Y; Gupta N; Matsuura I; Liu F; Zhou XZ; Lu KP; Gélinas C
Cancer Res; 2009 Jun; 69(11):4589-97. PubMed ID: 19458071
[TBL] [Abstract][Full Text] [Related]
10. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Fan Y; Gélinas C
Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
[TBL] [Abstract][Full Text] [Related]
11. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38.
Madrid LV; Mayo MW; Reuther JY; Baldwin AS
J Biol Chem; 2001 Jun; 276(22):18934-40. PubMed ID: 11259436
[TBL] [Abstract][Full Text] [Related]
12. Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappaB oncogenesis.
Liss AS; Tiwari R; Kralova J; Bose HR
Oncogene; 2010 Sep; 29(35):4925-37. PubMed ID: 20562914
[TBL] [Abstract][Full Text] [Related]
13. Discreet mutations from c-Rel to v-Rel alter kappaB DNA recognition, IkappaBalpha binding, and dimerization: implications for v-Rel oncogenicity.
Phelps CB; Ghosh G
Oncogene; 2004 Feb; 23(6):1229-38. PubMed ID: 14961076
[TBL] [Abstract][Full Text] [Related]
14. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
15. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.
Gupta N; Delrow J; Drawid A; Sengupta AM; Fan G; Gélinas C
Cancer Res; 2008 Feb; 68(3):808-14. PubMed ID: 18245482
[TBL] [Abstract][Full Text] [Related]
16. Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Munzert G; Kirchner D; Ottmann O; Bergmann L; Schmid RM
Leuk Lymphoma; 2004 Jun; 45(6):1181-4. PubMed ID: 15359998
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.
Liss AS; Bose HR
J Virol; 2002 May; 76(10):4928-39. PubMed ID: 11967310
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha activation of NF-kappa B requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel.
Martin AG; Fresno M
J Biol Chem; 2000 Aug; 275(32):24383-91. PubMed ID: 10823840
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.
White DW; Pitoc GA; Gilmore TD
Mol Cell Biol; 1996 Mar; 16(3):1169-78. PubMed ID: 8622661
[TBL] [Abstract][Full Text] [Related]
20. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).
Chen C; Edelstein LC; Gélinas C
Mol Cell Biol; 2000 Apr; 20(8):2687-95. PubMed ID: 10733571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
